載入中
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
前收盤價
US$11.61
+US$1.61 · +16.10%
盤中時間採用ET。市場資料可能有所延遲。
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
日內區間
目前US$11.61
52週區間
目前US$11.61
盤中時間採用ET。市場資料可能有所延遲。
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
日內區間
目前US$11.61
52週區間
目前US$11.61
| 項目（USD） | 2025會計年度 |
|---|---|
| 研究與開發 | 1.09億 USD |
| 銷售、一般及管理費用 | 4922.7萬 USD |
| 營業費用 | 1.58億 USD |
| 利息收入 | 1104.8萬 USD |
| 折舊和攤銷 | 31萬 USD |
| 營業利益 | −1.58億 USD |
| 淨利 | −1.49億 USD |
公司資料更新於 2026年10月11日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1817.83萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB1314.07萬0.01%1853億 USD0.03%US$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI1238.39萬0.13%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1219.87萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK750.33萬0.02%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF742.04萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO408.68萬0.02%180億 USD0.06%US$112.66+0.50%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM302.79萬5.48%5528.53萬 USD0.59%US$29.6009+1.06%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWORoundhill Investments - GLP-1 & Weight Loss ETFOZEMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
